These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA; Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087 [TBL] [Abstract][Full Text] [Related]
4. Leuconostoc as a Cause of Endophthalmitis Post-intravitreal Injection of Ranibizumab. Damasceno NP; Horowitz SA; Damasceno EF Ocul Immunol Inflamm; 2016; 24(1):118-9. PubMed ID: 24749654 [TBL] [Abstract][Full Text] [Related]
5. RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS. Arnett JJ; Brodowska K; Gallagher DS; Eller AW; Friberg TR; Anetakis AJ; Martel JN Retina; 2020 Sep; 40(9):1719-1723. PubMed ID: 31800459 [TBL] [Abstract][Full Text] [Related]
6. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Forooghian F; Albiani DA; Kirker AW; Merkur AB Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032 [TBL] [Abstract][Full Text] [Related]
7. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277 [TBL] [Abstract][Full Text] [Related]
8. Clinical features, microbiological profile and treatment outcome of patients with Corynebacterium endophthalmitis: review of a decade from a tertiary eye care centre in southern India. Joseph J; Nirmalkar K; Mathai A; Sharma S Br J Ophthalmol; 2016 Feb; 100(2):189-94. PubMed ID: 26124461 [TBL] [Abstract][Full Text] [Related]
9. Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. Albrecht E; Richards JC; Pollock T; Cook C; Myers L Br J Ophthalmol; 2011 Oct; 95(10):1385-8. PubMed ID: 21289020 [TBL] [Abstract][Full Text] [Related]
10. Severe Salceanu SO; Levy S; Cunningham R; Frimpong-Ansah K Indian J Ophthalmol; 2017 Nov; 65(11):1249-1251. PubMed ID: 29133669 [TBL] [Abstract][Full Text] [Related]
11. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL; Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198 [TBL] [Abstract][Full Text] [Related]
12. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]